Skip to main content

Table 4 Results of Cox model for progression-free and overall survival

From: Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

  

Progression-free survival

Overall survival

  

HR

95 % CI

P

HR

95 % CI

P

Age

≤60 years

1

     

>60 years

1.484

0.969-2.272

0.070

1.236

0.770-1.984

0.379

Smoking

Never

      

Ever

1.080

0.496-2.353

0.846

1.076

0.465-2.494

0.864

Performance status

ECOG 0

      

ECOG 1-2

1.110

0.661-1.862

0.694

2.381

1.215-4.673

0.012

Prior surgery

No

      

Yes

0.799

0.512-1.246

0.322

0.608

0.361-1.024

0.061

Prior radiotherapy

No

      

Yes

0.924

0.555-1.541

0.763

0.741

0.398-1.379

0.345

Prior chemotherapy

No

      

Yes

0.839

0.440-1.602

0.595

1.111

0.577-2.410

0.752

No. of metastases

One

      

≥Two

1.181

0.777-1.795

0.436

1.698

1.059-2.717

0.028

Lung metastasis

No

      

Yes

1.119

0.624-1.764

0.858

1.201

0.701-2.012

0.488

Liver metastasis

No

      

Yes

1.235

0.650-2.347

0.520

1.397

0.497-1.838

0.544

Treatment

CC

     

0.219

CP

0.786

0.515-1.198

0.263

0.745

0.465-1.192

  1. CC capecitabine plus cisplatin, CP capecitabine plus paclitaxel